

# Case Report

## Intravenous platelet therapy to patients with Lyme and associated diseases: A Case Series

Stephanie Peterson, MD (ILADS) – Avant Total Health, Lincoln, Nebraska | Tapley Holland – Bridging Biosciences

**INTRODUCTION:** Various pathogens (viruses, bacteria, fungi, parasites) have been implicated in the symptoms associated with chronic, autoimmune, and autoinflammatory diseases. In another eighteen patient case series, a single treatment of TruDOSE™ Platelet therapy showed complete serological negativization of these pathogens<sup>1</sup> and improved patients' symptoms. The current case series reports the symptom improvement following a single TruDOSE™ Platelet therapy treatment in thirty-three (33) consecutive patients with Lyme and associated diseases.

**OBJECTIVE:** To quantitatively examine pre and post symptoms following a single TruDOSE™ Platelet Therapy IV treatment using the Medical Symptom Questionnaire (MSQ) and Symptom Severity Scale (SSS) metrics.

**METHODS:** A prospective initiative was taken by a single site, direct primary care and integrative medicine clinic that attracts patients with acute and chronic vector-borne diseases. Thirty-three (33) consecutive patients with confirmed Lyme and associated diseases breakdown as follows:

(Lyme - *Borrelia* spp. **81.6% [n=31]**; Mold and mycotoxin illness **63.2% [n=24]**; SAR-COV-2 (Longhauers) **50.0% [n=19]**; retroviruses **50% [n=19]**; Bartonella spp. **47.4% [n=18]**; Babesia spp. **36.8% [n=14]**; Mycoplasma pneumoniae **36.8% [n=14]**; parasites **36.8% [n=14]**; Epstein-Barr Virus **23.7% [n=9]**; Cytomegalovirus **23.7% [n=9]**; Herpes simplex viruses **15.8% [n=6]**; Rickettsia **13.2% [n=5]**; Chlamydia pneumoniae **10.5% [n=4]**)

To assess symptom improvement of the TruDOSE™ IV Platelet Therapy, all patients completed the MSQ and SSS questionnaires before treatment and 4 weeks post treatment.

### RESULTS:

	# of patients	Avg. % of years treating	Avg. MSQ % improvement	Avg. SSS% Improvement
<b>Overall</b>	33	33.4 %	40.2%	30.6%
<b>3 or less pathogens</b>	3 (9%)	21.7%	40.5%	15.0%
<b>4-6 pathogens</b>	4 (12%)	38.6%	40.0%	21.1%
<b>7 or more pathogens</b>	26 (79%)	34.7%	42.1%	38.2%

**DISCUSSION:** Treatment of patients with vector borne infections present numerous challenges for the health care practitioner. These difficulties pale by comparison to those patients who have been traumatized and discouraged seeking help for conditions within the conventional medical system. A new treatment modality that can provide relatively rapid incremental relief and assist the patient to better tolerate their protocols holds potential to have significant impact on their quality of life. Laboratory evidence of treatment success is not always reliable as an indicator of disease remission or cure. Therefore, the current author sought to evaluate the TruDOSE™ IV Platelet Therapy's effectiveness in bringing about rapid symptom improvement to a desperate patient population.

The MSQ is a 72-question comprehensive measure of medical symptoms more likely to affect daily functioning and quality of life. The SSS has 36 questions chosen to be an assessment tool that can utilized in a treatment clinic to monitor progress at each visit. Pre-treatment average baseline scores for the MSQ and SSS were **72.1** (14 to 206) and **32.9** (8 to 86) respectively. Surprisingly, the 4 week follow up revealed an overall **40.2%** (72.1 to 43.1) **MSQ** and **30.6%** (32.9 to 23.2) **SSS** symptom improvement, respectively. The most severe patients with chronic vector borne illness usually have more than one pathogen or condition simultaneously. Shockingly, **79%** (26/33) of these patients had a combination of seven or more pathogens. Furthermore, this severe patient group represented the most improved symptom scores on both the MSQ (**42.1%**) and SSS (**38.2%**) questionnaires, respectively.

The authors also found interesting the number of years this patient group had been treating their individual conditions. The patient ages ranged from 9 – 80 years and the time spent treating their individual condition ranged from 1 year to 64 years. When looking at the length of time the patient had spent in treatment of their conditions to their age, it was found that one-third (**33.4%**) of their life had been spent living and treating their individual condition. **81%** (27/33) of these patients treated were over the age of 40. Time invested in treatments equates to losses in quality of life, career, finances, relationships, and social isolation which can be contributing factors to other disease conditions. While anecdotal, the current patient group reported and commented improvement to the aforementioned domains which, when compared to symptom relief, are just as valuable in their eyes.

In summary, TruDOSE™ IV Platelet Therapy demonstrated a significant difference to this patient population. First, while it was hopeful, it was not expected to have such a symptom improvement considering the severity and length of time this patient population has been experiencing their individual condition. Secondly, these patients were able to reduce or eliminate many supplements and medications at the 4 week time point. This not only translates to a long-term cost savings for the patient, but an indicator towards complete healing. Lastly, the systemic benefits and recalibration from the IV treatment either revealed or removed issues allowing the current author to improve and refine each patients' individual treatment plan. While these results are early, the TruDOSE™ IV Platelet Therapy improved symptoms and provided hope through a minimal risk treatment modality that harnesses the body's own natural healing mechanisms.

<sup>1</sup> Serological negativization of 8 different pathogens associated with autoimmune diseases following a single intravenous TruDOSE™ platelet therapy treatment.